A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis

Veterinary Dermatology

Volumn 24, Issue 6, 2013, Pages

  Cosgrove, Sallie B ^a   Wren, Jody A ^a   Cleaver, Dawn M ^a   Walsh, Kelly F ^a   Follis, Stacey I ^a   King, Vickie I ^a   Tena, Jezaniah Kira S ^a   Stegemann, Michael R ^b  

^a ZOETIS   (United States)

^b Zoetis Veterinary Medicine Research and Development   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; OCLACITINIB; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL; ANIMAL DISEASE; ARTICLE; ATOPIC DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOG DISEASES; DOGS; FEMALE; MALE; PYRIMIDINES; SULFONAMIDES;

EID: 84888048954     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/vde.12088     Document Type: Article

References (42)

1. ® Pet Insurance website. Top 10 pet medical conditions of 2010. Available at: http://press.petinsurance.com/pressroom/02222011Pet_Conditions_2010.aspx. Accessed Dec 28, 2012.
2. Lund EM, Armstrong PJ, Kirk CA et al. Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. J Am Vet Med Assoc 1999; 214: 1336-1341.
3. Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol 2006; 114: 207-208.
4. Griffin CE, DeBoer DJ. The ACVD task force on canine atopic dermatitis (XIV): clinical manifestations of canine atopic dermatitis. Vet Immunol Immunopathol 2001; 81: 255-269.
5. Marsella R, Sousa CA, Gonzales AJ et al. Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. J Am Vet Med Assoc 2012; 241: 194-207.
6. Olivry T, DeBoer DJ, Favrot C et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol 2010; 21: 233-248.
7. Favrot C, Linke M, Mueller R. Development of a questionnaire to assess the impact of atopic dermatitis on health-related quality of life of affected dogs and their owners. Vet Dermatol 2010; 21: 64-70.
8. Olivry T, Mueller RS. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol 2003; 14: 121-146.
9. Scott DW, Griffin CE, Campbell KL. Dermatologic therapy. In: Muller and Kirk's Small Animal Dermatology. 7th ed. St Louis: Saunders Elsevier, 2013; 150-153.
10. Plumb DC. Glucocorticoid agents, general information. In: Plumb's Veterinary Drug Handbook. 4th ed. Ames: Blackwell Publishing, 2002; 387-389.
11. Olivry T, Sousa C. The ACVD task force on canine atopic dermatitis (XX): glucocorticoid pharmacotherapy. Vet Immunol Immunopathol 2001; 81: 317-322.
12. Olivry T, Bizikova P. A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008-2011 update. Vet Dermatol 2013; 24: 97-117, e26-e26.
13. ®; Zoetis) is a novel Janus kinase inhibitor that has activity against canine pro-allergic and pro-inflammatory cytokines. Vet Dermatol 2013; 24: 384-385. (abstract).
14. Carmi-Levy I, Homey B, Soumelis V. A modular view of cytokine networks in atopic dermatitis. Clin Rev Allergy Immunol 2011; 41: 245-253.
15. Ong PY, Leung DY. Immune dysregulation in atopic dermatitis. Curr Allergy Asthma Rep 2006; 6: 384-389.
16. Gonzales AJ, Humphrey WR, Messamore JE et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol 2013; 24: 48-53, e11-e12.
17. Fleck T, Humphrey W, Coscarelli E et al. Comparison of the janus kinase (JAK) inhibitor, oclacitinib, and prednisolone in canine models of pruritus. Vet Dermatol 2012; 23(Suppl 1): 38 (abstract).
18. Cosgrove S, Wren J, Cleaver D et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 2013; 24: 479-e114.
19. Apoquel® product label. Available at: https://online.zoetis.com/US/EN/Products/Documents/Apoquel_PI.pdf. Accessed Jul 16, 2013.
20. International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH), Good Clinical Practice Website. Available at: http://www.vichsec.org/en/topics.htm. Accessed Dec 28, 2012.
21. Olivry T, Marsella R, Iwasaki T et al. Validation of CADESI-03, a severity scale for clinical trials enrolling dogs with atopic dermatitis. Vet Dermatol 2007; 18: 78-86.
22. Olivry T, Rivierre C, Jackson HA et al. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Vet Dermatol 2002; 13: 77-87.
23. Olivry T, Steffan J, Fisch RD et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. J Am Vet Med Assoc 2002; 221: 370-377.
24. Prélaud P, Guaguère E, Alhaidari Z et al. Re-evaluation of diagnostic criteria of canine atopic dermatitis. Rev Med Vet (Toulouse) 1998; 149: 1057-1064.
25. Gross TL, Ihrke PJ, Walder EJ et al. Diseases of the dermis. Skin Diseases of the Dog and Cat, 2nd edition. Oxford: Blackwell Publishing, 2005: 200-206.
26. Epinette WW. Treatment of atopic eczema with staphylococcal toxoid. J Am Med Assoc 1988; 259: 2759-2760.
27. Collard WT, Hummel BD, Malpas PB et al. Single and multiple dose pharmacokinetics of oclacitinib maleate in the dog. In: Proceedings of the American Academy of Veterinary Pharmacology and Therapeutics Biennial Meeting. Potomac, MD, USA: 2013.
28. Olivry T, Mueller R, Nuttall T et al. Determination of CADESI-03 thresholds for increasing severity levels of canine atopic dermatitis. Vet Dermatol 2008; 19: 115-119.
29. Rybnicek J, Lau-Gillard P, Harvey R et al. Further validation of a pruritus severity scale for use in dogs. Vet Dermatol 2008; 20: 115-122.
30. Olivry T, Foster AP, Mueller RS et al. Interventions for atopic dermatitis in dogs: a systematic review of randomized controlled trials. Vet Dermatol 2010; 21: 4-22.
31. Steffan J, Alexander D, Brovedani F et al. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: a parallel, blinded, randomized controlled trial. Vet Dermatol 2003; 14: 11-22.
32. Dip R, Carmichael J, Letellier I et al. Concurrent short-term use of presnisolone with cyclosporine A accelerates pruritus reduction and improvement in clinical scoring in dogs with atopic dermatitis.BMC Vet Res 2013; 9: 173.
33. Bryden SL, Burrows AK, Rème C et al. Efficacy of a 0.0584% hydrocortisone acetate spray (Cortavance) for the management of pedal pruritus in atopic dogs; a pilot study. Vet Dermatol 2008; 19(Suppl 1): 40 (abstract).
34. Carlotti DN, Boulet M, Ducret J et al. The use of recombinant omega interferon therapy in canine atopic dermatitis; a double-blind controlled study. Vet Dermatol 2009; 20: 405-411.
35. Nuttall TJ, McEwan NA, Bensignor E et al. Comparable efficacy of a topical 0.0584% spray and oral ciclosporin in treating canine atopic dermatitis. Vet Dermatol 2012; 23: 4-10, e1-e2.
36. DeBoer DJ, Hillier A. The ACVD task force on canine atopic dermatitis (XV): fundamental concepts in clinical diagnosis. Vet Immunol Immunopathol 2001; 81: 271-276.
37. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-287.
38. Malpas PB, Franks RK, King VL et al. Margin of safety study of oclacitinib maleate administered to adult laboratory dogs for 26 weeks at multiples of the therapeutic dose. In: Proceedings of the American Academy of Veterinary Pharmacology and Therapeutics Biennial Meeting. Potomac, MD, USA: 2013.
39. Thamm D, Vail D. Chapter 16: Mast cell tumors. In: Withrow SJ, MacEwen EG, eds. Saunders Small Animal Clinical Oncology. 3rd edition. Philadelphia: W.B. Saunders Co., 2001; 261-282.
40. Novartis Animal Health website. Atopica [indications]. Available at: http://www.ah.novartis.com/products/en/atopica_dog.shtml. Accessed Jan 25, 2013.
41. Committee for Medicinal Products for Veterinary use (CVMP). Guidelines on statistical principles for veterinary clinical trials. EMA/CVMP/EWP 20 September 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/01/WC500120834.pdf. Accessed Sept 13, 2013.
42. Alshurafa M, Briel M, Akl EA et al. Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One. website. Available at http://dx.doi.org/10.1371%2Fjournal.pone.0049163. Accessed Aug 20, 2013.